Iovance Biotherapeutics, Inc. (IOVA)

Trade IOVA now with
7/18/2019 8:05:10 AM Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein As Chief Medical Officer
6/11/2019 7:11:20 AM Iovance Biotherapeutics Appoints Athena Countouriotis To Board
4/3/2019 7:09:24 AM Iovance Biotherapeutics To Present New Data From Ongoing Studies Of TIL Therapy At 2019 ASCO Meeting
2/26/2019 7:29:00 AM Iovance Biotherapeutics: FDA Grants Fast Track Designation For LN-145 For Cervical Cancer
11/6/2018 8:13:19 AM Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data From The Lifileucel Metastatic Melanoma Trial
10/18/2018 7:12:44 AM Iovance Biotherapeutics And MaSTherCell Enter New Three-year Manufacturing Services Agreement
10/17/2018 7:05:15 AM Iovance Biotherapeutics Closes Public Offering Of 25.30 Mln Shares Of Common Stock
10/12/2018 7:46:04 AM Iovance Biotherapeutics Prices Public Offering Of 22 Mln Shares At $9.97 Per Share
10/11/2018 4:09:52 PM Iovance Biotherapeutics Announces Proposed Public Offering Of Common Stock
8/16/2018 8:04:17 AM Iovance Biotherapeutics Announces Trial Updates With Collaborators MD Anderson And Moffitt Cancer Center
6/7/2018 8:08:43 AM Iovance Biotherapeutics Says First Patient Dosed In Europe For Ongoing C-144-01 Phase 2 Trials In Metastatic Melanoma
6/6/2018 8:04:13 AM Advaxis Appoints Molly Henderson As EVP And CFO
4/10/2018 8:45:12 AM B. Riley FBR Upgrades Iovance Biotherapeutics, Inc. (IOVA) To Buy From Neutral With $22 Price Target
1/30/2018 6:41:48 AM In The Spotlight: Iovance